RecruitingPhase 1 / Phase 2NCT04711200
3
studies recruiting now
as of 7 Sept 2026
41
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
7 Nov 2023
most recent study posted
among recruiting studies
Recruiting trials
RecruitingEarly phase 1NCT06119490
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
RecruitingNCT03659227
Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Showing the 3 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Toxic epidermal necrolysis studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Toxic epidermal necrolysis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Toxic epidermal necrolysis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
6 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Human Immunoglobulin G (Flebogamma dif (previously flebogammadif))
Phase 2Infliximab (Flixabi)
Phase 1/2Clobetasol
Phase 1/2Palifermin (Kepivance)
Phase 1 (early)Tofacitinib
Phase 1 (early)Abrocitinib (Cibinqo)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).